ALT
Altimmune, Inc. Common Stock
Nasdaq · usd
Altimmune, Inc. Common Stock (ALT) trades at $2.08 (-1.90%) as of 9:30:14 AM EST on Nov 10, 2026, -18.77% over the past month. Market cap is $412.38M, with 10.4 days to cover in short interest.
Stock performance
How Altimmune, Inc. Common Stock (ALT) stock has performed from one day to one year, with its 52-week range.
- 1D
- +1.92%
- 1W
- +4.95%
- 1M
- -18.77%
- YTD
- -41.27%
- 1Y
- -50.47%
- 52-wk range
- $1.91 – $6.44
Key statistics
Today's trading snapshot for ALT: day range, open, previous close, volume and market cap.
- Day range
- $2.12 – $2.13
- Open
- $2.12
- Prev close
- $2.12
- Volume
- 68.65K
- Market cap
- $412.38M
- Shares out
- 194.52M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Altimmune, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 13302.50
- P/B
- 0.87
- P/FCF
- —
- ROE
- -19.4%
- ROA
- -17.5%
- Debt/Equity
- 0.07
- Div yield
- 0.00%
As of Nov 9, 2026
8-K filings
Material corporate events Altimmune, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Credit facilityOct 29, 2026
As a result of occurrence and satisfaction of the Tranche 3 Milestone, (i) the Amortization Date and interest-only period has been extended to June 1, 2028, and (ii) pursuant to the Minimum Cash covenant set forth in Section 7.19(a)(i) of the Loan Agreement, the Company shall maintain Qualified Cash in an amount greater than or equal to the outstanding principal amount of the Term Loan Advances multiplied by 60%.
- Director appointmentOct 27, 2026
On October 23, 2026, the Board of Directors, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Peter Greenleaf and Alex Howarth as directors of the Board effective November 2, 2026, and approved an increase in its size from nine to eleven directors.
- Executive officer appointmentSep 29, 2026
On September 24, 2026, the Board of Directors (the "Board") of Altimmune, Inc. (the "Company") appointed Richard Menziuso as the Company's Vice President, Global Controller and Principal Accounting Officer effective as of September 29, 2026.
- Clinical trial resultsJul 28, 2026
On July 28, 2026, Altimmune, Inc. (the "Company") issued a press release announcing the positive topline results from the RECLAIM Phase 2 trial evaluating pemvidutide 2.4 mg dose, an investigational balanced glucagon/GLP-1 dual receptor agonist, in patients with moderate to severe alcohol use disorder (AUD). The trial met its primary endpoint with a highly statistically significant reduction in heavy drinking days per week (HDD) versus placebo, with positive results across important secondary endpoints, including a two-level reduction in the World Health Organization Risk Drinking Level and zero HDDs, both of which are U.S. Food and Drug Administration (FDA) registrational endpoints, as well as a reduction in phosphatidyl ethanol levels. A generally favorable safety and tolerability profile was observed in the trial.
- Lease agreementJun 16, 2026
The Company has entered into an office lease agreement for the New Jersey headquarters where the Company will make rent payments of approximately $300,000 annually for the 5-year lease term.
Dividend history and stock splits
Altimmune, Inc. Common Stock's recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 1-for-30Sep 14, 2018
- 1-for-10May 4, 2017
- 1-for-50Jul 25, 2007
ALT short interest
How heavily ALT is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 10.4
- Short interest
- 42.23M
- Avg volume
- 4.05M
As of · reported to FINRA twice monthly.
ALT news
The latest news and headlines about Altimmune, Inc. Common Stock (ALT).
- Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026positiveGlobeNewswire Inc.· Nov 5, 2026
- Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options | DelveInsightpositiveGlobeNewswire Inc.· Oct 20, 2026
- Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?neutralZacks Investment Research· Oct 7, 2026
- Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?positiveZacks Investment Research· Sep 11, 2026
- Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsightpositiveGlobeNewswire Inc.· Jun 8, 2026
Frequently asked questions
What is the Altimmune, Inc. Common Stock (ALT) stock price today?
Altimmune, Inc. Common Stock (ALT) is trading at $2.08 (-1.90% on the day) as of 9:30:14 AM EST on Nov 10, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Altimmune, Inc. Common Stock?
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development…
What is the short interest in ALT?
As of Oct 15, 2026, ALT has 42.23M shares short and 10.4 days to cover.
What exchange is ALT listed on?
Altimmune, Inc. Common Stock (ALT) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of ALT with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a ALT analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.